The West Metro-Minneapolis Community Clinical Oncology Program (WMMCCOP) represents a consortium of seven hospitals which, through its NCI-funded Community Hospital Oncology Program (""""""""CHOP"""""""") and operational CCOP, has already developed a common approach to the management of cancer patients and has an established mechanism for entering and following patients on treatment and cancer control protocols. The consortium has a community-wide computerized data management system (TUMORS/CHOP-DS) capable of prospective data collection. The community offers 6 HMO programs, all of which are represented among these seven consortium hospitals. Together, the seven hospitals see an average of 4700 new analytic cancer patients per year. The thirty-four core investigators, representing oncology, hematology, immunology, radiation oncology, urology, and colorectal surgery, have worked extensively together on cancer program development and protocol management. The WMMCCOP staff is qualified and trained in oncology and data management, and has been involved in the development of the current program structure and operation. During the most recent NCI-funded grant year (6/88-5/89), the WMMCCOP entered 1069 patients (134 treatment credits/54 cancer control credits onto NCI-approved studies). The WMMCCOP intends to: sustain a region wide community and hospital consortium which provides the community with the most recent advances in cancer control and treatment. This will be accomplished through expansion of the current consortium to include new hospitals not currently participating in the WMMCCOP, increased involvement of primary care physicians and surgeons; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, ECOG, NSABP, FCCC, the Minnesota Department of Health, and M.D. Anderson; improve and expand the current WMMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; encourage minority group participation; increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. During the first year of operation under this grant period, WMMCCOP investigators intend to accrue 250 credits onto NCI-approved cancer treatment and control studies, exceeding the minimum requirements for both types of studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (54))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Park Nicollet Institute
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7

Showing the most recent 10 out of 76 publications